WO2012140577A1 - Modified release pharmaceutical compositions of desvenlafaxine - Google Patents
Modified release pharmaceutical compositions of desvenlafaxine Download PDFInfo
- Publication number
- WO2012140577A1 WO2012140577A1 PCT/IB2012/051761 IB2012051761W WO2012140577A1 WO 2012140577 A1 WO2012140577 A1 WO 2012140577A1 IB 2012051761 W IB2012051761 W IB 2012051761W WO 2012140577 A1 WO2012140577 A1 WO 2012140577A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- desvenlafaxine
- modified release
- pharmaceutical composition
- pharmaceutically acceptable
- benzoate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- This present invention relates to modified release pharmaceutical compositions comprising Desvenlafaxine and a process for preparation thereof.
- Serotonin-norepinephrine reuptake inhibitors are a class of antidepressant drugs used in the treatment of major depression and other mood disorders. They are also used to treat anxiety disorders, obsessive-compulsive disorder (OCD), attention deficit hyperactivity disorder (ADHD), chronic neuropathic pain, fibromyalgia syndrome (FMS), and for the relief of menopausal symptoms.
- OCD obsessive-compulsive disorder
- ADHD attention deficit hyperactivity disorder
- FMS fibromyalgia syndrome
- Serotonin-norepinephrine reuptake inhibitors include but not limited to venlafaxine, Desvenlafaxine, milnacipran, duloxetine, sibutramine, levomilnacipran and sibutramine.
- Desvenlafaxine is Serotonin-norepinephrine reuptake inhibitors and chemically, Desvenlafaxine is chemically named ( ⁇ )-l-[2-(dimethylamino)-l-(4- hydroxyphenyl)ethyl]cyclohexanol, is a major metabolite of venlafaxine and has been shown to inhibit norepinephrine and serotonin uptake.
- Desvenlafaxine which can also be referred to as O-Desmethylvenlafaxine or desmethylvenlafaxine, is represented by the following structural formula:
- O-desmethyl venlafaxine is a major metabolite of venlafaxine and has been shown to inhibit norepinephrine and serotonin uptake.
- Desvenlafaxine was exemplified as a fumarate salt in U.S. Pat. No. 4,535,186. However, the fumarate salt of O-desmethyl-venlafaxine has unsuitable physicochemical and permeability characteristics. O-desmethyl-venlafaxine is also exemplified as a free base in International Patent Publication No. WO 00/32555.
- U.S. Pat. No. 6,673,838 disclose different crystalline forms of Desvenlafaxine Succinate mainly Form I, II, III and IV. Further it discloses amorphous form of Desvenlafaxine Succinate.
- U.S. Pat. No. 7,820,716 discloses Form V and Form F of Desvenlafaxine Succinate.
- Salt formation provides a means of altering the physicochemical and resultant biological characteristics of a drug without modifying its chemical structure.
- a salt form can have a dramatic influence on the properties of the drug.
- the selection of a suitable salt is partially dictated by yield, rate and quantity of the crystalline structure.
- hygroscopicity, stability, solubility and the process profile of the salt form are important considerations. The identification of a salt form that exhibits a suitable combination of properties can be difficult.
- the Succinate monohydrate form of Desvenlafaxine has been incorporated into an extended release hydro-gel tablet, which reduces adverse effects such as nausea, vomiting, diarrhea, and abdominal pain.
- Formulations describing the use of hydroxypropyl methylcellulose (HPMC) as the hydrogel matrix have been described in U.S. Pat. No. 7,291,347.
- US Patent Application No 20050175698 provides an enteric coated multiparticulate form of Desvenlafaxine that reduces undesirable characteristics associated with Desvenlafaxine and the hydrogel formulation thereof.
- These Desvenlafaxine multiparticulates are composed of Desvenlafaxine Succinate, Desvenlafaxine formate, or combinations thereof.
- this formulation also allows more convenient dosing to patients who have difficulty swallowing solid foods.
- US Patent Application No 20100210719 describes stable amorphous O- desmethylvenlafaxine Succinate solid dispersions with one or more pharmaceutically acceptable carriers.
- US Patent Application No 20100330172 discloses matrix controlled-release pharmaceutical formulation comprising Desvenlafaxine Succinate, having an MMD of between about 5 micrometer and about 100 micrometer and matrix rate-controlling pharmaceutically acceptable polymer.
- US Patent Application No 20110046231 provides pharmaceutical composition comprising a solid state form of O-desmethylvenlafaxine salt and one or more pharmaceutically acceptable excipients, wherein the salt of O-desmethylvenlafaxine is an oxalate salt, a Benzoate salt or a lactate salt.
- US Patent Application No 20070014859 discloses superbioavailable DVS (O- desmethylvenlafaxine Succinate) sustained release composition
- a core containing at least DVS and a water insoluble filler in an oral dosage unit having a delayed release of at least about one hour and a sustained release over multiple hours to provide a total release of greater than about 85% within about 12 to about 14 hours.
- the main object of invention is to provide modified release pharmaceutical composition of Desvenlafaxine.
- Another object of invention is modified release pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.
- Another object of invention is modified release pharmaceutical composition
- Desvenlafaxine one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein ds 0 particle size of Desvenlafaxine is upto about 80 microns.
- Another object of invention is modified release pharmaceutical composition
- composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.
- Another object of invention is modified release pharmaceutical composition
- Desvenlafaxine one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein ds 0 particle size of Desvenlafaxine is upto about 80 microns such that composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.
- modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s).
- modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), such that ds 0 particle size of Desvenlafaxine upto about 80 microns.
- modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.
- Another object of invention is modified release pharmaceutical composition
- a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein ds 0 particle size of Desvenlafaxine is upto about 80 microns such that composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.
- the present invention provides modified release pharmaceutical compositions comprising Desvenlafaxine and a process for preparation thereof and their use in medicines.
- the invention relates to modified release pharmaceutical compositions comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof, which is bioequivalent to extended release composition of Desvenlafaxine Succinate in a bioavailability study in humans.
- C max and AUC of the modified release composition comprising Desvenlafaxine Benzoate are independent of food effect.
- the present invention relates to provide modified release pharmaceutical composition of Desvenlafaxine and a process for preparation thereof.
- Desvenlafaxine may be used in the form of base, pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) thereof.
- salts refers to salts comprise but not limited to which are prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids
- suitable non-toxic acids include inorganic and organic acids such as acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, formic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methane-sulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toulenesufonic acids and the like.
- Desvenlafaxine is in the salt form. More preferably Desvenlafaxine salt is Benzoate, Succinate, glutarate & palmitate.
- Desvenlafaxine Benzoate is in crystalline form or in amorphous form or a mixture thereof. It is to be understood for the purpose of invention that Desvenlafaxine Benzoate may be present in the form of solvates with organic solvents like ethanol, isopropanol or hydrate like monohydrate, dihydrate or enantiomers.
- Desvenlfaxine Benzoate can be prepared by methods disclosed in Indian Patent Application no. 0761/KOL/2011 are hereby incorporated in its entirety.
- Desvenlafaxine Benzoate is in crystalline form characterized by a powder X-ray diffraction pattern having at least one peak at about 5.4, 10.75, 16.6, 18.0, 19.2, 23.32 ⁇ 0.2 degrees 2 ⁇ substantially as depicted in Figure 1.
- Desvenlafaxine Benzoate is in crystalline form characterized by a powder X-ray diffraction pattern having peaks at about 5.4, 10.75, 16.6, 18.0, 19.2, 23.32 ⁇ 0.2 degrees 2 ⁇ substantially as depicted in Figure 1.
- Desvenlafaxine Benzoate is in crystalline form characterized by a powder X-ray diffraction pattern having peaks at about 5.4, 9.5, 10.75, 16.1, 16.6, 17.3, 18.0, 19.2, 20.4, 23.32 ⁇ 0.2 degrees 2 ⁇ substantially as depicted in Figure 1.
- Desvenlafaxine Benzoate is in crystalline form characterized by a powder X-ray diffraction pattern substantially in accordance with Figure 1.
- Desvenlafaxine Benzoate is in crystalline form characterized by a powder X-ray diffraction pattern having peaks at about 5.4, 9.5, 10.7, 16.1, 16.6, 17.3, 18.0, 19.2, 20.4, 21.5, 23.3, 24.9, 28.3, 29.9 ⁇ 0.2 degrees 2 ⁇ .
- Desvenlafaxine Benzoate has solubility in water of greater than 30mg/ml, preferably the aqueous solubility of the Desvenlafaxine Benzoate is at least about 50 mg/ml at 25° C, more preferably, the aqueous solubility of Desvenlafaxine Benzoate is about 60 mg/ml at 25° C.
- Desvenlafaxine Succinate has solubility in water of greater than 30mg/ml, preferably the aqueous solubility of the Desvenlafaxine Succinate is about 35 mg/ml at 25° C.
- Desvenlafaxine used in pharmaceutical compositions of invention in an amount of which is safe, well tolerated in patients with acceptable adverse effect profiles and are those in common practice and known to person skilled in the art.
- Desvenlafaxine used to treat or prevent central nervous system disorders including, but not limited to depression (including but not limited to major depressive disorder, bipolar disorder and dysthymia), fibromyalgia, anxiety, panic disorder, agoraphobia, post traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, ***e and alcohol addiction, sexual dysfunction, (including premature ejaculation), borderline personality disorder, chronic fatigue syndrome, incontinence (including fecal incontinence, overflow
- the dosage amount useful to treat, prevent, inhibit or alleviate each of the aforementioned conditions will vary with the severity of the condition to be treated and the route of administration.
- the dose and dose frequency will also vary according to age, body weight, response and past medical history of the individual human patient.
- a modified release pharmaceutical composition according to the invention comprises but is not limited to tablets (single layered tablets, multilayered tablets, mini tablets, bioadhesive tablets, caplets, matrix tablets, tablet within a tablet, mucoadhesive tablets, modified release tablets, pulsatile release tablets, and timed release tablets), pellets, beads, granules, sustained release formulations, capsules, microcapsules, tablets in capsules, microspheres, matrix formulations, microencapsulation.
- modified release used in pharmaceutical compositions of invention means controlled release, extended release, sustained release, delayed release or combination of any of these techniques.
- modified release pharmaceutical composition of inventions may be any formulation technique wherein release of the active substance from the composition is modified to occur at a slower rate than that from an immediate release composition.
- a modified release pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.
- a modified release pharmaceutical composition comprising Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipients(s) thereof.
- a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.
- a modified release pharmaceutical composition comprising crystalline form of Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.
- a modified release pharmaceutical composition comprising crystalline form of Desvenlafaxine Benzoate characterized by a powder X-ray diffraction pattern having at least one peak at about 5.4, 10.75, 16.6, 18.0, 19.2, 23.32 ⁇ 0.2 degrees 2 ⁇ substantially as depicted in Figure 1 , one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.
- a modified release pharmaceutical composition comprising crystalline form of Desvenlafaxine Benzoate characterized by a powder X-ray diffraction pattern having peak at about 5.4, 10.75, 16.6, 18.0, 19.2, 23.32 ⁇ 0.2 degrees 2 ⁇ substantially as depicted in Figure 1, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.
- a modified release pharmaceutical composition comprising crystalline form of Desvenlafaxine Benzoate characterized by a powder X-ray diffraction pattern having peaks at about 5.4, 9.5, 10.75, 16.1, 16.6, 17.3, 18.0, 19.2, 20.4, 23.32 ⁇ 0.2 degrees 2 ⁇ substantially as depicted in Figure 1, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.
- a modified release pharmaceutical composition comprising crystalline form of Desvenlafaxine Benzoate characterized by a powder X-ray diffraction pattern substantially in accordance with Figure 1, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.
- a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate in crystalline form characterized by a powder X-ray diffraction pattern having peaks at about 5.4, 9.5, 10.7, 16.1, 16.6, 17.3, 18.0, 19.2, 20.4, 21.5, 23.3, 24.9, 28.3, 29.9 ⁇ 0.2 degrees 2 ⁇ , one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.
- a modified release pharmaceutical composition comprising amorphous form of Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.
- a modified release pharmaceutical composition comprising Desvenlafaxine glutarate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.
- a modified release pharmaceutical composition comprising Desvenlafaxine palmitate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.
- a modified release pharmaceutical composition comprises Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein release modifying agent(s) is from about 1 % to about 95 % based on total weight of composition.
- a modified release pharmaceutical composition comprises Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein release modifying agent(s) is present in an amount less than about 55% based on total weight of composition.
- a modified release pharmaceutical composition comprises Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein release modifying agent(s) is from about 1 % to about 95 % based on total weight of composition.
- the hydrophilic release modifying agent(s) according to invention comprises but not limited cellulose derivatives, alginic acid derivatives, polysaccharides, alkylene oxides or mixtures thereof.
- hydrophilic release modifying agent(s) comprises celluloses or their salts or derivatives thereof, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (hypromellose), sodium carboxymethyl cellulose, alginic acid or their salts and derivatives thereof, carbomer (Carbopol(TM)), polyethyleneoxide, xanthan gum, guar gum, locust bean gum, poly vinyl acetate, polyvinyl alcohol, lactose.
- Carbopol(TM) Carbopol(TM)
- polyethyleneoxide xanthan gum
- guar gum locust bean gum
- poly vinyl acetate polyvinyl alcohol
- lactose lactose
- the hydrophobic release modifying agent(s) according to the invention comprises but not limited to hydrogenated vegetable oils, polymethacrylates, ethyl cellulose or mixtures thereof.
- hydrophobic release modifying agent(s) comprises Ammonio methacrylate copolymers type A and B as described in USP, methacrylic acid copolymer type A, B and C as described in USP, Polyacrylate dispersion 30% as described in Ph.
- Polyvinyl acetate dispersion ethylcellulose, cellulose acetate, cellulose propionate (lower, medium or higher molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly(methyl methacrylate), poly(ethyl methacrylate), poly (butyl methacrylate), poly(isobutyl methacrylate), and poly(hexyl methacrylate).
- waxes such as beeswax, carnauba wax, microcrystalline wax, and ozo
- the average particle size of the particles of Desvenlafaxine or a pharmaceutically acceptable salt thereof, in the modified release pharmaceutical composition of the invention is between about 5 microns to about 120 microns, preferably between about 7 microns to about 100 microns and more preferably about 10 microns to about 80 microns.
- the terms "average particle size”, '3 ⁇ 4 0 " and “mass mean diameter” can be used interchangeably.
- the average particle size i.e. the average equivalent diameter, is defined as the diameter where 50 mass % of the particles of the Desvenlafaxine have a larger equivalent diameter, and the other 50 mass-% have a smaller equivalent diameter.
- the “average particle size” also refers to the median particle diameter based on mass (i.e. the particle diameter where one half of the mass of particles is contributed by particles with a lesser diameter and one half of the mass of particles is contributed by particles with a greater diameter).
- the particle size can be measured using various commonly available methods such as measurement using light (eg. light-scattering methods or turbidimetric methods), sedimentation methods (eg. pipette analysis using an Andreassen pipette, sedimentation scales, photo-sedimentometers or sedimentation in a centrifugal force), pulse methods (eg. Coulter counter), or sorting by means of gravitational or centrifugal force.
- light eg. light-scattering methods or turbidimetric methods
- sedimentation methods eg. pipette analysis using an Andreassen pipette, sedimentation scales, photo-sedimentometers or sedimentation in a centrifugal force
- pulse methods eg. Coulter counter
- a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein ds 0 particle size of Desvenlafaxine is upto about 80 microns.
- a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein ds 0 particle size of Desvenlafaxine Benzoate is from about 10 microns to about 80 microns.
- a modified release pharmaceutical composition comprising Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein dso particle size of Desvenlafaxine Succinate is upto about 80 microns.
- a modified release pharmaceutical composition comprising Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein ds 0 particle size of Desvenlafaxine Succinate is upto about 50 microns.
- a modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s).
- a modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), such that dso particle size of Desvenlafaxine is upto about 80 microns.
- a modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein release of Desvenlafaxine is predominantly modified by coating.
- a modified release pharmaceutical composition having release of Desvenlafaxine in two or more steps at different release rates which comprises a) a modified release part A comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) and b) a modified release part B comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s).
- a modified release pharmaceutical composition having release of Desvenlafaxine in two or more steps at different release rates which comprises a) a modified release part A comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) and b) a modified release part B comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein part A is coated with part B.
- a modified release pharmaceutical composition is multi-layered tablet.
- a modified release pharmaceutical composition comprises a inert core which is loaded with drug layer comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein Desvenlafaxine Benzoate layer being further coated with one or more release modifying layer comprising release modifying agent(s) and one or more pharmaceutically acceptable excipient(s).
- a modified release pharmaceutical composition comprises a inert core which is loaded with drug layer comprising Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein Desvenlafaxine Succinate layer being further coated with one or more release modifying layer comprising release modifying agent(s) and one or more pharmaceutically acceptable excipient(s).
- the inert core comprises but not limited to sugar sphere or pellets, microcrystalline cellulose sphere, sugar/starch core or any suitable material.
- drug layer and release modifying layer may be separated by one or more separating layers.
- the separating layer comprises one or more pharmaceutically acceptable excipients and one or more hydrophilic agent(s), hydrophobic agent(s) or combination thereof.
- the hydrophilic agent(s) according to invention comprises but not limited to cellulose derivatives, alginic acid derivatives, polysaccharides, alkylene oxides or mixtures thereof.
- hydrophilic agent(s) comprises celluloses or their salts or derivatives thereof, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (hypromellose), sodium carboxymethyl cellulose, alginic acid or their salts and derivatives thereof, carbomer (Carbopol(TM)), polyethyleneoxide, xanthan gum, guar gum, locust bean gum, poly vinyl acetate, polyvinyl alcohol, lactose.
- Carbopol(TM) Carbopol(TM)
- polyethyleneoxide xanthan gum, guar gum, locust bean gum
- poly vinyl acetate polyvinyl alcohol
- lactose lactose
- the hydrophobic agent(s) according to the invention comprises but not limited to hydrogenated vegetable oils, polymethacrylates, ethyl cellulose or mixtures thereof.
- hydrophobic agent(s) comprises Ammonio methacrylate copolymers type A and B as described in USP, methacrylic acid copolymer type A, B and C as described in USP, Polyacrylate dispersion 30% as described in Ph.
- Polyvinyl acetate dispersion ethylcellulose, cellulose acetate, cellulose propionate (lower, medium or higher molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly(methyl methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), and poly(hexyl methacrylate).
- waxes such as beeswax, carnauba wax, microcrystalline wax, and ozo
- compositions of invention comprise but not limited to diluents, binders, pH stabilizing agents, disintegrants, surfactants, glidants and lubricants.
- excipient(s) employed will depend upon how much active agent is to be used. One excipient(s) can perform more than one function.
- Binders as used in the invention comprises but are not limited to, starches such as potato starch, wheat starch, corn starch; microcrystalline cellulose such as products known under the registered trademarks Avicel, Filtrak, Heweten or Pharmacel; celluloses such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose (HPMC), ethyl cellulose, sodium carboxy methyl cellulose; natural gums like acacia, alginic acid, guar gum; liquid glucose, dextrin, povidone, syrup, polyethylene oxide, polyvinyl pyrrolidone, poly-N-vinyl amide, polyethylene glycol, gelatin, poly propylene glycol, tragacanth, combinations thereof and other materials known to one of ordinary skill in the art and mixtures thereof.
- starches such as potato starch, wheat starch, corn starch
- microcrystalline cellulose such as products known under the registered trademarks Avicel, Filtrak, Heweten or Pharmacel
- Fillers or diluents as used in the invention comprises but not limited to confectioner's sugar, compressible sugar, dextrates, dextrin, dextrose, fructose, lactitol, mannitol, sucrose, starch, lactose, xylitol, sorbitol, talc, microcrystalline cellulose, calcium carbonate, calcium phosphate dibasic or tribasic, calcium sulphate, and the like can be used.
- Lubricants as used in the invention comprises but not limited to Mg, Al ,Ca or Zn stearate, polyethylene glycol, glyceryl behenate, mineral oil, sodium stearyl fumarate, stearic acid, hydrogenated vegetable oil and talc.
- Glidants comprises but not limited to, silicon dioxide; magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate, calcium silicate, magnesium silicate, colloidal silicon dioxide, silicon hydrogel and other materials known to one of ordinary skill in the art.
- Disintegrants comprises but not limited to starches; clays; celluloses; alginates; gums; cross-linked polymers, e.g., cross-linked polyvinyl pyrrolidone or crospovidone, e.g., POLYPLASDONE XL, cross-linked sodium carboxymethylcellulose or croscarmellose sodium, e.g., AC-DI-SOL from FMC; and cross-linked calcium carboxymethylcellulose; soy polysaccharides; and guar gum.
- Use of disintegrant according to the invention facilitates in the release of drug in the latter stage and thereby completely releasing the drug from the dosage form.
- the pharmaceutical composition may optionally contain a surface-active agent.
- the preferred agent is copolymers composed of a central hydrophobic chain of polyoxypropylene (poly (propylene oxide)) and polyoxyethylene (poly (ethylene oxide)) that is well known as poloxamer.
- other agents may also be employed such as dioctyl sodium sulfosuccinate (DSS), triethanolamine, sodium lauryl sulphate (SLS), polyoxyethylene sorbitan and poloxalkol derivatives, quaternary ammonium salts or other pharmaceutically acceptable surface-active agents known to one ordinary skilled in the art.
- the pharmaceutical composition can be formed by various processes known in the art but not limited to such as by dry granulation, wet granulation, melt granulation, direct compression, double compression, extrusion spheronization, layering and the like.
- the solvent(s) used in wet granulation include all the solvents well known in the art or the mixtures thereof.
- a modified pharmaceutical composition of invention comprises one or more coating comprising but not limited to modified release coating, sustained release coating, extended release coating, enteric coating, partial enteric coating or leaky enteric coating, bioadhesive coating and similar coatings known in the art. These coatings may help the pharmaceutical composition to release the drug at and for the required time.
- coatings comprise coating agent(s) selected from hydrophilic or hydrophobic agent(s) or the combinations thereof.
- the hydrophobic agent(s) in the coating comprises but not limited to Ammonio methacrylate copolymers type A and B as described in USP, methacrylic acid copolymer type A, B and C as described in USP, Polyacrylate dispersion 30% as described in pH.
- Polyvinyl acetate dispersion ethylcellulose, cellulose acetate, cellulose propionate (lower, medium or higher molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly(methyl methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), and poly(hexyl methacrylate).
- waxes such as beeswax, carnauba wax, microcrystalline wax, and ozo
- the hydrophilic agent(s) in the coating comprises but not limited to celluloses or their salts or derivatives thereof, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (hypromellose), sodium carboxymethyl cellulose, alginic acid or their salts and derivatives thereof, carbomer (Carbopol(TM)), polyethyleneoxide, xanthan gum, guar gum, locust bean gum, poly vinyl acetate, polyvinyl alcohol, lactose,
- these hydrophilic polymers also act as pore forming agent.
- These coating comprises one or more excipients selected from the group comprising coating agents, opacifiers, taste-masking agents, fillers, polishing agents, colouring agents, antitacking agents and the like.
- the pharmaceutical composition can be coated by a wide variety of methods. Suitable methods include compression coating, coating in a fluidized bed or a pan and hot melt (extrusion) coating. Such methods are well known to those skilled in the art.
- a stable modified release pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.
- a modified release pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.
- a modified release pharmaceutical composition comprising Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein composition releases about 75% of Desvenlafaxine Succinate in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.
- a modified release pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein dso particle size of Desvenlafaxine is upto about 80 microns such that composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.
- a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein dso particle size of Desvenlafaxine Benzoate is from about 5 microns to about 80 microns such that composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.
- a modified release pharmaceutical composition comprises from about 10 % to about 50% by weight of Desvenlafaxine Succinate and less than about 60 % of release modifying agent(s) based upon total weight of composition, wherein dso particle size of Desvenlafaxine Succinate is upto about 50 microns such that composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.
- a modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.
- a modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein ds 0 particle size of Desvenlafaxine is upto about 80 microns such that composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.
- In another embodiment of the invention is a method of lowering the incidence of nauseau, vomiting, diarrhea, abdominal pain, headache, vaso-vagal malaise, and/or trismus resulting from the oral administration of venlafaxine, Desvenlafaxine, or a salt of Desvenlafaxine other than Desvenlafaxine Benzoate to a patient.
- the method includes orally administering to a patient in need thereof a therapeutically effective amount of Desvenlafaxine Benzoate.
- In another embodiment of the invention is a method of lowering the incidence of nausea, vomiting, diarrhea, abdominal pain, headache, vaso-vagal malaise, and/or trismus resulting from the oral administration of Desvenlafaxine Benzoate to a patient.
- the method includes orally administering to a patient in need thereof a therapeutically effective amount of a sustained release oral dosage form comprising Desvenlafaxine Benzoate having a peak blood plasma level of less than about 225 ng/ml.
- Desvenlafaxine Benzoate may also be provided in combination with venlafaxine.
- the dosage of venlafaxine is preferably about 75 mg to about 350 mg/day and more preferably about 75 mg to about 225 mg/day.
- the dosage of venlafaxine is about 75 mg to about 150 mg/day.
- the ratio of Desvenlafaxine to venlafaxine will vary from patient to patient depending upon a patient's response rate, but generally will be at least 6: 1 Desvenlafaxine to venlafaxine.
- Desvenlafaxine Benzoate is less fluffy than that of Desvenlafaxine Succinate. So, the dusting is less during manufacturing of the drug product and which gives ease of handling the drug substance as compared to the Succinate and there is a minimum chance of drug loss during manufacturing process and hence gives an advantage over Succinate salt. Further, the particle size distribution of Desvenlafaxine Benzoate drug substance is smaller as compared to Desvenlafaxine Succinate drug substance. Hence, the distribution of drug substance in the drug product is uniform and gives no chance of variation in content uniformity of the final drug product/dosage form.
- Pristiq ® is the brandname for the extended release composition of Desvenlafaxine Succinate, 50 mg and 100 mg marketed by Wyeth Pharmaceuticals Inc. (Now Pfizer) Philadelphia, PA 19101.
- a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein the modified release composition provides C max (peak plasma levels) of upto about 225 ng/ml.
- a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein the modified release composition provides C max (peak plasma levels) of upto about 300 ng/ml.
- a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof, wherein Cmax and AUC of the modified release composition are within the limit of 80 % to 125 % of Cmax and AUC of the extended release composition of Desvenlafaxine Succinate.
- Cmax means maximum plasma concentration of Desvenlafaxine produced by the ingestion of the modified release composition of invention or the marketed Pristiq ® (Extended Release Composition of Desvenlafaxine Succinate) composition. C max or peak plasma level may be used interchangeably.
- AUC means area under the plasma concentration-time curve of Desvenlafaxine produced by the ingestion of the modified release composition of invention or the marketed Pristiq ® (Extended Release Composition of Desvenlafaxine Succinate).
- a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein, T max of the modified release composition is comparable to Tmax of the extended release composition of Desvenlafaxine Succinate.
- Tmax means time to the maximum observed plasma concentration of Desvenlafaxine produced by the ingestion of the modified release composition of invention or the marketed Pristiq ® (Extended Release Composition of Desvenlafaxine Succinate).
- a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein, T ma x of the modified release composition is less than about 8 hours.
- Cmax and AUC were comparable for the modified release composition of Desvenlafaxine Benzoate when administered after a high-fat meal and under fasting condition as the ratios falls between 80-125%.
- a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein C max and AUC of the modified release composition are independent of food effect.
- a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof, which is bioequivalent to Pristiq® tablet in a bioavailability study in humans.
- a modified release pharmaceutical composition of the present invention can be used to treat or prevent central nervous system disorders including, but not limited to depression (including but not limited to major depressive disorder, bipolar disorder and dysthymia), fibromyalgia, anxiety, panic disorder, agoraphobia, post traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, ***e and alcohol addiction, sexual dysfunction, (including premature ejaculation), borderline personality disorder, chronic fatigue syndrome, incontinence (including fecal incontinence, overflow incontinence, passive incontinence, reflex incontinence, stress urinary incontinence, urge incontinence, urinary exertional incontinence and urinar
- the following examples are illustrative of the present invention, and the examples should not be considered as limiting the scope of this invention in any way, as these examples and other equivalents thereof will become apparent to those versed in the art, in the light of the present disclosure, and the accompanying claims.
- the X-ray diffraction pattern for Desvenlafaxine Benzoate was measured using X-ray diffractometer.
- Non- Aqueous coating with a build up of l-10%w/w.
- Hypromellose and Dibasic calcium phosphate / MCC using Povidone as binder are examples of Hypromellose and Dibasic calcium phosphate / MCC using Povidone as binder.
- Desvenlafaxine Succinate and Hypromellose or Xanthum gum are dry mixed.
- step 2 Add Microcrystalline Cellulose / Dibasic calcium phosphate to step 1 and mix well.
- Non- Aqueous coating with a build up of l-10%w/w.
- Desvenlafaxine Succinate and Ethyl Cellulose are dry mixed.
- step 2 Add Microcrystalline Cellulose / Dibasic calcium phosphate to step 1 and mix well.
- Step 3 Coat the mixture of Step 2 on sugar spheres of step 1 using DCM/IPA solution to form drug layer.
- Example 11 ngredients %w/w
- Example 12 ngredients %w/w
- Example 13 ingredients %w/w
- Table 1 shows the dissolution profile of Desvenlafaxine Benzoate Modified Release Tablets of Example 1 of the present invention carried out in 900 ml of 0.9% NaCl in water for 24 hours using Apparatus USP-I (Basket) at 100 rpm speed.
- the release profile (cumulative % of drug released) is given in Table 1.
- Table 2 16 Not Less Than 75% Table 2 given below shows the dissolution profile of Desvenlafaxine Succinate Modified Release Tablets of Example 5 of the present invention carried out in 900 ml of 0.9% NaCl in water for 24 hours using Apparatus USP-I (Basket) at 100 rpm speed.
- the release profile (cumulative % of drug released) is given in Table 1.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112013025766A BR112013025766A2 (en) | 2011-04-12 | 2012-04-11 | desvenlafaxine modified release pharmaceutical compositions |
AU2012241407A AU2012241407B2 (en) | 2011-04-12 | 2012-04-11 | Modified release pharmaceutical compositions of Desvenlafaxine |
NZ609568A NZ609568B2 (en) | 2011-04-12 | 2012-04-11 | Modified release pharmaceutical compositions of desvenlafaxine |
MX2013011884A MX2013011884A (en) | 2011-04-12 | 2012-04-11 | Modified release pharmaceutical compositions of desvenlafaxine. |
KR1020137027449A KR20140030156A (en) | 2011-04-12 | 2012-04-11 | Modified release pharmaceutical compositions of desvenlafaxine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN530/KOL/2011 | 2011-04-12 | ||
IN530KO2011 | 2011-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012140577A1 true WO2012140577A1 (en) | 2012-10-18 |
Family
ID=46062650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2012/051761 WO2012140577A1 (en) | 2011-04-12 | 2012-04-11 | Modified release pharmaceutical compositions of desvenlafaxine |
Country Status (5)
Country | Link |
---|---|
KR (1) | KR20140030156A (en) |
AU (1) | AU2012241407B2 (en) |
BR (1) | BR112013025766A2 (en) |
MX (1) | MX2013011884A (en) |
WO (1) | WO2012140577A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104352469A (en) * | 2014-11-20 | 2015-02-18 | 哈尔滨圣吉药业股份有限公司 | Desvenlafaxine succinate sustained-release tablets and preparation method thereof |
EP3677254A1 (en) * | 2018-12-27 | 2020-07-08 | Sanovel Ilac Sanayi ve Ticaret A.S. | Solid oral pharmaceutical compositions of desvenlafaxine |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4535186A (en) | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
WO2000032555A1 (en) | 1998-12-01 | 2000-06-08 | Sepracor Inc. | Derivatives of (+)-venlafaxine and methods of preparing and using the same |
US6673838B2 (en) | 2001-02-12 | 2004-01-06 | Wyeth | Succinate salt of O-desmethyl-venlafaxine |
US20040106576A1 (en) | 1999-04-06 | 2004-06-03 | Sepracor Inc. | Derivatives of venlafaxine and methods of preparing and using the same |
US20050175698A1 (en) | 2004-02-06 | 2005-08-11 | Wyeth | Multiparticulate O-desmethylvenlafaxine salts and uses thereof |
US7001920B2 (en) | 2002-06-10 | 2006-02-21 | Wyeth | Formate salt of O-desmethyl-venlafaxine |
WO2006104791A1 (en) * | 2005-03-31 | 2006-10-05 | Wyeth | O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof |
US20070014859A1 (en) | 2005-07-15 | 2007-01-18 | Wyeth | Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate |
WO2009017813A1 (en) | 2007-08-02 | 2009-02-05 | Teva Pharmaceutical Industries Ltd. | O-desmethyl venlafaxine saccharinate |
WO2009049354A1 (en) * | 2007-10-16 | 2009-04-23 | Alphapharm Pty Ltd | Controlled-release pharmaceutical formulation |
WO2009053840A2 (en) | 2007-10-22 | 2009-04-30 | Actavis Group Ptc Ehf | Solid forms of (±)-o-desmethylvenlafaxine salts |
WO2009095431A1 (en) | 2008-01-29 | 2009-08-06 | Lek Pharmaceuticals D.D. | Novel salts of o-desmethyl-venlafaxine |
WO2009136756A2 (en) | 2008-05-08 | 2009-11-12 | 제일약품주식회사 | Novel {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof, a production method therefor and a pharmaceutical composition for preventing and treating central nervous system disorders containing the same as an active component |
WO2010008735A2 (en) | 2008-06-16 | 2010-01-21 | Teva Pharmaceutical Industries Ltd. | Solid states of o-desmethylvenlaf axine salts |
US20100210719A1 (en) | 2007-07-12 | 2010-08-19 | Dr. Reddy's Laboratories Ltd. | O-desmethylvenlafaxine |
US7820716B2 (en) | 2007-01-08 | 2010-10-26 | Mai De Ltd | Crystalline polymorphs of desvenlafaxine succinate and their preparations |
-
2012
- 2012-04-11 MX MX2013011884A patent/MX2013011884A/en unknown
- 2012-04-11 WO PCT/IB2012/051761 patent/WO2012140577A1/en active Application Filing
- 2012-04-11 AU AU2012241407A patent/AU2012241407B2/en not_active Ceased
- 2012-04-11 KR KR1020137027449A patent/KR20140030156A/en not_active Application Discontinuation
- 2012-04-11 BR BR112013025766A patent/BR112013025766A2/en not_active IP Right Cessation
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4535186A (en) | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
WO2000032555A1 (en) | 1998-12-01 | 2000-06-08 | Sepracor Inc. | Derivatives of (+)-venlafaxine and methods of preparing and using the same |
US20040106576A1 (en) | 1999-04-06 | 2004-06-03 | Sepracor Inc. | Derivatives of venlafaxine and methods of preparing and using the same |
US7291347B2 (en) | 2001-02-12 | 2007-11-06 | Wyeth | Succinate salt of O-desmethyl-venlafaxine |
US6673838B2 (en) | 2001-02-12 | 2004-01-06 | Wyeth | Succinate salt of O-desmethyl-venlafaxine |
US7001920B2 (en) | 2002-06-10 | 2006-02-21 | Wyeth | Formate salt of O-desmethyl-venlafaxine |
US20050175698A1 (en) | 2004-02-06 | 2005-08-11 | Wyeth | Multiparticulate O-desmethylvenlafaxine salts and uses thereof |
WO2006104791A1 (en) * | 2005-03-31 | 2006-10-05 | Wyeth | O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof |
US20070014859A1 (en) | 2005-07-15 | 2007-01-18 | Wyeth | Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate |
US7820716B2 (en) | 2007-01-08 | 2010-10-26 | Mai De Ltd | Crystalline polymorphs of desvenlafaxine succinate and their preparations |
US20100210719A1 (en) | 2007-07-12 | 2010-08-19 | Dr. Reddy's Laboratories Ltd. | O-desmethylvenlafaxine |
WO2009017813A1 (en) | 2007-08-02 | 2009-02-05 | Teva Pharmaceutical Industries Ltd. | O-desmethyl venlafaxine saccharinate |
WO2009049354A1 (en) * | 2007-10-16 | 2009-04-23 | Alphapharm Pty Ltd | Controlled-release pharmaceutical formulation |
US20100330172A1 (en) | 2007-10-16 | 2010-12-30 | Alphapharm Pty Ltd | Controlled-release pharmaceutical formulation |
WO2009053840A2 (en) | 2007-10-22 | 2009-04-30 | Actavis Group Ptc Ehf | Solid forms of (±)-o-desmethylvenlafaxine salts |
US20110046231A1 (en) | 2007-10-22 | 2011-02-24 | Actavis Group Ptc Ehf | Solid forms of (±)-o-desmethylvenlafaxine salts |
WO2009095431A1 (en) | 2008-01-29 | 2009-08-06 | Lek Pharmaceuticals D.D. | Novel salts of o-desmethyl-venlafaxine |
WO2009136756A2 (en) | 2008-05-08 | 2009-11-12 | 제일약품주식회사 | Novel {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof, a production method therefor and a pharmaceutical composition for preventing and treating central nervous system disorders containing the same as an active component |
WO2010008735A2 (en) | 2008-06-16 | 2010-01-21 | Teva Pharmaceutical Industries Ltd. | Solid states of o-desmethylvenlaf axine salts |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104352469A (en) * | 2014-11-20 | 2015-02-18 | 哈尔滨圣吉药业股份有限公司 | Desvenlafaxine succinate sustained-release tablets and preparation method thereof |
EP3677254A1 (en) * | 2018-12-27 | 2020-07-08 | Sanovel Ilac Sanayi ve Ticaret A.S. | Solid oral pharmaceutical compositions of desvenlafaxine |
Also Published As
Publication number | Publication date |
---|---|
MX2013011884A (en) | 2013-11-21 |
NZ609568A (en) | 2015-10-30 |
AU2012241407A1 (en) | 2013-05-02 |
BR112013025766A2 (en) | 2016-12-20 |
KR20140030156A (en) | 2014-03-11 |
AU2012241407B2 (en) | 2015-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20090042967A (en) | Formulations of flibanserin and method for manufacturing the same | |
JP2020500176A (en) | Pharmaceutical preparations | |
JP2020500176A5 (en) | ||
WO2003082805A1 (en) | Low water-soluble venlafaxine salts | |
US20090269402A1 (en) | Modified release composition of at least one form of venlafaxine | |
TWI491395B (en) | Oral dosage formulation containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders | |
EP1487429A2 (en) | Compositions of venlafaxine base | |
US20130143897A1 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
AU2008314489B2 (en) | Controlled-release pharmaceutical formulation | |
US20140010883A1 (en) | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor | |
JP2023181218A (en) | Extended release midodrine hydrochloride compositions and methods of use | |
AU2012241407B2 (en) | Modified release pharmaceutical compositions of Desvenlafaxine | |
CN114867469A (en) | Oral pharmaceutical composition comprising carbamate compound and preparation method thereof | |
US20050244498A1 (en) | Modified-release compositions of at least one form of venlafaxine | |
EP2391353A1 (en) | Pharmaceutical compositions of trimetazidine | |
EP2191822A1 (en) | Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine | |
EP3677254B1 (en) | Solid oral pharmaceutical compositions of desvenlafaxine | |
NZ609568B2 (en) | Modified release pharmaceutical compositions of desvenlafaxine | |
US8481596B2 (en) | Polymomorph of desvenlafaxine benzoate | |
WO2010015911A1 (en) | Sustained release pharmaceutical compositions of ropinirole and process for preparation thereof | |
CA2509124A1 (en) | Modified-release composition of at least one form of venlafaxine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12720609 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2012241407 Country of ref document: AU Date of ref document: 20120411 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/011884 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20137027449 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12720609 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013025766 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013025766 Country of ref document: BR Kind code of ref document: A2 Effective date: 20131004 |